Klin Farmakol Farm. 2010;24(2):103-105
Abatacept and it’s use in rheumatoid arthritis
- III. interní klinika FN a LF UP Olomouc
Abatacept is a new type of biological drug for rheumatoid arthritis blocking the co stimulation system of T lymphocytes activation
CD28-CD80/86 via recombinant molecule CTLA4 and Fc fragment of IgG1. The drug is given in 30 minutes intravenous infusion at the day 0,
and then after 2 and 4 weeks following by the maintenance dose every 4 weeks. Abatacept has demonstrated in various populations of
patients with rheumatoid arthritis (methotrexate naive, methotrexate failure, anti TNF alpha blocker (s) failure) efficacy in activity and
radiographic progression control. It has a favorable safety profile with mild increase in infection frequency. European Medicine Agency
(EMEA) approved abatacept for the moderate and severe forms of active rheumatoid arthritis in combination with methotrexate, who
failed to respond to of did not tolerate anti TNF alpha blocker (s).
Keywords: rheumatoid arthritis, biological therapy, abatacept
Published: July 1, 2010 Show citation
References
- Bečvář R, Vencovský J, Němec P, Suchý D, Procházková L, Pavelka K. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Účinnost a strategie léčby. Čes Revmatol 2007; 15: 73-90.
- Gomez-Reino JJ, Carmona L. BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: Supp: S29.
Go to original source... 
Go to PubMed... - Hyrich KL, Lunt M, Watson KD, et al. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20. Go to original source... Go to PubMed...
- Edwards JCW, Szczepanski L, Szechinski J, et al. The efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581. Go to original source... Go to PubMed...
- Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915. Go to original source... Go to PubMed...
- Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569. Go to original source... Go to PubMed...
- Bristol-Myers Squibb. ORENCIA. Product information. www.emea.europa.eu.
- Bristol-Myers Squibb. Orencia (abatacept) prescribing information. www.orencia.com.
- Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-2271. Go to original source... Go to PubMed...
- Kremer JM, Genant H, Moreland L, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-876. Go to original source... Go to PubMed...
- Westhovens R, Luggen M, Russell A, et al. Abatacept provides durable improvements in RA disease status and a consistent safety profile through 3 years in the aim and attain trials. Reumatoplogy 2008; 47(Suppl. 2): 46.
- Emery P, Kremer JM, Moreland R, et al. Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate. Rheumatology 2008; 47(Suppl. 2): 48.
- Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor in inhibition. N Engl J Med 2005; 353: 1114-1123. Go to original source... Go to PubMed...
- Genovese MC, Schiff M, Luggen M, et al. Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Arthritis Rheum 2006; 54(Suppl 9): 247.
- Weinblatt M, Schiff M, Goldman A, et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2007; 66: 228-234. Go to original source... Go to PubMed...
- Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 2008; 67: 1096-1103. Go to original source... Go to PubMed...
- Schiff M, Keiserman M, Codding C, et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54(Suppl.): 43.
- Schiff M, Pritchard C, Teng J, et al. The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: results from the ARRIVE trial. Ann Rheum Dis 2007; 66(Suppl. II): 89.
- Smitten A, Simon R, Qi K, et al. Hospitalized infections in the abatacept RA clinical development program: An epidemiological assessment with > 10,000 person-years of exposure. Artrhitis Rheum 2008; 58(Suppl.): S786-S787.
- Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807-2816. Go to original source... Go to PubMed...
- Smitten A, Simon R, Qi K, et al. Malignancies in the abatacept RA clinical development program: An updated epidemiological assessment with > 10,000 person-years of exposure. Artrhitis Rheum 2008; 58(Suppl.): 787.
- Corbo M, Valencia X, Raymond R, et al. Subcutaneuous administration of abatacept in patients withj rheumatoid arthritis: Pharmacokinetics, Safety, and Immunogenicity. Ann Rheum Dis 2009; 68(Suppl. 3): 574.
- Westhovens R, Kremer J, Emery P, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naive patients with RA. Ann Rheum Dis 2008; 67(Suppl II.): 341.
- Genant HK, Peterfy C, Westhovens R, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA. Ann Rheum Dis 2009; 68(Suppl 3.): 440.